|13.77|| +0.35 / +2.61%|
RedHill Biopharma Ltd. is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of clinical-stage, proprietary formulations and combinations of existing drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer and related conditions. The Company's current pipeline of proprietary products includes: (i) RHB-104 - an oral combination therapy for the treatment of Crohn's disease, with an ongoing Phase III study, (ii) RHB-105 - an oral combination therapy for Helicobacter pylori infection, with an ongoing Phase III study; (iii) RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.; (iv) RHB-103 - an oral thin film formulation of rizatriptan for acute migraines with U.S. NDA under FDA review; (v) RHB-102 - a once-daily oral pill formulation of ondansetron for the prevention of nausea and vomiting and, (vi) RHB-101 - a once-daily oral formulation of carvedilol. RedHill Biopharma was founded on August 3, 2009 and is headquartered in Tel Aviv, Israel.
|Dror Ben-Asher||Chairman & Chief Executive Officer|
|Ori Shilo||Director, Deputy CEO-Finance & Operations|
|Ira N. Kalfus||Medical Director|
|Reza Fathi||Senior Vice President-Research & Development|
|Thomas A. Lang||Vice President-Regulatory & Clinical Affairs|